There are currently 441 active clinical trials seeking participants for Breast Cancer research studies. The states with the highest number of trials for Breast Cancer participants are California, Ohio, Illinois and Michigan.
The C-MERIT Screening Cohort: Contrast-enhanced Mammography for Breast Cancer Screening and Risk Assessment in Women With Dense Breasts
NCT05667532
Recruiting
To learn whether a new imaging technology, Contrast-Enhanced Mammography (CEM), compared to standard mammography, can better detect breast cancers in women with dense breasts
Gender:
FEMALE
Ages:
Between 30 years and 75 years
Trial Updated:
12/18/2024
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Breast Cancer
Register for Updates
Study of the CHK1 Inhibitor BBI-355, an EcDNA-directed Therapy (ecDTx), in Subjects with Tumors with Oncogene Amplifications
NCT05827614
Recruiting
BBI-355 is an oral, potent, selective checkpoint kinase 1 (or CHK1) small molecule inhibitor in development as an ecDNA (extrachromosomal DNA) directed therapy (ecDTx). This is a first-in-human, open-label, 3-part, Phase 1/2 study to determine the safety profile and identify the maximum tolerated dose and recommended Phase 2 dose of BBI-355 administered as a single agent or in combination with select therapies.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/18/2024
Locations: UCLA Medical Center, Los Angeles, California +15 locations
Conditions: Non-small Cell Lung Cancer, Non-Small Cell Lung Adenocarcinoma, Non-Small Cell Squamous Lung Cancer, Head and Neck Squamous Cell Carcinoma, Esophageal Cancer, Gastric Cancer, Breast Cancer, Bladder Cancer, Ovarian Cancer, Endometrial Cancer, Liposarcoma
Register for Updates
Refining Local-Regional Therapy for IBC
NCT04636710
Recruiting
This Feasibility study is trying to determine: * If Lymphoscintigraphy (imaging of the lymphatic drainage patterns) is effective in demonstrating the drainage to the sentinel lymph nodes in patients with inflammatory breast cancer. * The likelihood of identifying the sentinel lymph nodes in the operating room, using both blue dye and the radioactive substance used for lymphoscintigraphy. * The incidence of lymphedema (arm swelling which occurs after lymph node surgery) in women with inflammator... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
12/16/2024
Locations: Dana Farber Cancer Institute, Boston, Massachusetts
Conditions: Breast Cancer, Inflammatory Breast Cancer, Sentinel Lymph Node
Register for Updates
ZAP-IT: ZN-c3 + Carboplatin + Pembrolizumab in MTNBC
NCT06351332
Recruiting
This research is being done to evaluate the safety and effectiveness of a drug currently known as Azenosertib (ZN-C3) in combination with the drugs carboplatin and pembrolizumab in metastatic triple-negative breast cancer. The names of the study drugs involved in this study are: * Azenosertib (a type of WEE1 inhibitor) * Carboplatin (a type of platinum compound) * Pembrolizumab (a type of monoclonal antibody)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/16/2024
Locations: Dana-Farber Cancer Institute, Boston, Massachusetts
Conditions: Breast Cancer, Breast Cancer Female, Triple Negative Breast Cancer, Hormone Receptor Negative Malignant Tumor Breast Triple, HER2-negative Breast Cancer
Register for Updates
Phase IIB Trial of Bazedoxifene Plus Conjugated Estrogens
NCT04821141
Recruiting
Women at risk for development of breast cancer and experiencing vasomotor menopausal symptoms (hot flashes) will be randomized to bazedoxifene (BZA) plus conjugated estrogens (CE) for 6 months versus a wait list control. Two risk factors for development of breast cancer will be studied pre-study and after 6 months: fibroglandular volume (FGV) on mammogram as assessed by Volpara software and proliferation by Ki-67 immunocytochemistry in benign breast tissue acquired by random periareolar fine nee... Read More
Gender:
FEMALE
Ages:
Between 45 years and 64 years
Trial Updated:
12/16/2024
Locations: City of Hope Medical Center, Duarte, California +4 locations
Conditions: Risk Reduction, Breast Cancer
Register for Updates
Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)
NCT05501886
Recruiting
This is a Phase 3, open-label, randomized, clinical trial evaluating the efficacy and safety of gedatolisib plus fulvestrant with or without palbociclib for the treatment of patients with locally advanced or metastatic HR+/HER2- breast cancer following progression on or after CDK4/6 and aromatase inhibitor therapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/16/2024
Locations: University of Alabama at Birmingham, Birmingham, Alabama +216 locations
Conditions: Breast Cancer
Register for Updates
A Study Comparing Cancer Imaging Approaches in People with Lobular Breast Cancer
NCT06557148
Recruiting
The purpose of this study to compare two types of cancer imaging scans to see which is better at detecting and monitoring metastatic ILC. This study will compare PET/CT (positron emission tomography/computed tomography) scans using the radiotracer fluorine 18 (18F)-fluoroestradiol (FES) with a standard imaging approach for detecting and monitoring ILC, PET/CT scans using the radiotracer 18F-fluorodeoxyglucose (FDG). These scans will be referred to as FES PET/CT scans and FDG PET/CT scans.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/13/2024
Locations: Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey +6 locations
Conditions: Breast Cancer, Lobular Breast Carcinoma, Breast Carcinoma, Metastatic Breast Cancer, Metastatic Lobular Breast Carcinoma, Metastatic Breast Carcinoma
Register for Updates
Brain [18F]-FES PET/CT in Patients With Estrogen-Receptor Positive Breast Cancer
NCT06072807
Recruiting
The goal of this interventional study is to optimize the protocol of FES PET/CT in Estrogen Receptor positive Breast cancer patients with Brain metastases. Patients will undergo MRI of the brain and FDG PET/CT brain as part of standard of care for radiation treatment planning. An additional 18F-FES PET/CT brain scan will be completed before this standard of care radiation treatment. Patients will be followed prospectively with clinical and MRI assessments per standard-of-care for a total of 12 m... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
12/13/2024
Locations: New York-Presbyterian/Weill Cornell Medical Center, New York, New York
Conditions: Breast Cancer, Brain Metastases
Register for Updates
Identifying Underserved Individuals inTexas With Hereditary Cancer Risk Using Mobile Mammography Units and Telegenetics.
NCT05649072
Recruiting
Identifying women at risk for hereditary cancer potentiates prevention, early detection or personalised treatment against cancer. We using mobile mammography units will provide genetic sceening and testing services to underserved women coming for thier mammograms to these units.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
12/13/2024
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Ovarian Cancer, Breast Cancer, Colorectal Cancer
Register for Updates
Trial of PreoperAtive Radiation (TOPAz): a Randomized Trial Comparing Hypofractionated Versus Conventionally Fractionated Preoperative Radiation Followed by Mastectomy with Immediate Autologous Breast Reconstruction with Integrated Nanomechanical Biomarker Evaluation
NCT05774678
Recruiting
To compare the outcomes of and responses to 2 different radiation therapy schedules (the standard radiation amount and number of doses versus less radiation and fewer doses) that are being given before having breast cancer surgery (cancer removal and reconstruction).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/12/2024
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Breast Cancer
Register for Updates
Locally AblatiVe TherApy in OLigO-pRogressive SOlid TUmorS (VALOROUS)
NCT06103669
Recruiting
This is a phase 2 pragmatic study that evaluates the clinical benefit of continuing systemic therapy with the addition of locally ablative therapies for oligo-progressive solid tumors as the primary objective. The primary outcome measure is the time to treatment failure (defined as time to change in systemic failure or permanent discontinuation of therapy) following locally ablative therapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/12/2024
Locations: University of California, Davis, Sacramento, California
Conditions: Breast Cancer, Oligoprogressive, Head and Neck Cancer, Sarcoma, Other Cancer
Register for Updates
Prospective Evaluation of Pencil Beam Scanning Proton Therapy for Previously Irradiated Tumors
NCT05313191
Recruiting
The goal of this clinical research trial is to study the use of differing investigational doses and scheduling for Proton Therapy for tumors previously treated with radiation therapy. Generally, when patients are first treated for cancer with radiation therapy, they are treated with traditional photon (or x-ray) radiation therapy, which uses high-energy waves to kill tumor cells. In some cases, the cancer either returns or a new tumor can present in a different part of the body. With the usual r... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/12/2024
Locations: The New York Proton Center, New York, New York
Conditions: CNS Cancer, Head and Neck Cancer, GI Cancer, Gynecologic Cancer, Prostate Cancer, Thoracic Cancer, Breast Cancer
Register for Updates